Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GRAL
stocks logo

GRAL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 104.705
sliders
Low
38.00
Averages
60.86
High
83.71
Current: 104.705
sliders
Low
38.00
Averages
60.86
High
83.71
Canaccord
Kyle Mikson
Buy
maintain
$85 -> $105
2025-11-17
Reason
Canaccord
Kyle Mikson
Price Target
$85 -> $105
2025-11-17
maintain
Buy
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Grail to $105 from $85 and keeps a Buy rating on the shares. The firm target increase is driven by significant progress/plans to expand adoption levels (and reimbursement) for the Galleri multi-cancer early detection (MCED) test.
Morgan Stanley
Equal Weight
maintain
$38 -> $85
2025-11-16
Reason
Morgan Stanley
Price Target
$38 -> $85
2025-11-16
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Grail to $85 from $38 and keeps an Equal Weight rating on the shares. The firm updated the company's estimates post the Q3 report. It cites Grail's longer-term opportunity with Galleri for the target increase. The multi-cancer early detection test has significant long-term potential, but there are also inherent risks associated with novel technologies, the analyst tells investors in a research note.
Guggenheim
Subbu Nambi
Neutral -> Buy
upgrade
$100
2025-11-12
Reason
Guggenheim
Subbu Nambi
Price Target
$100
2025-11-12
upgrade
Neutral -> Buy
Reason
Guggenheim analyst Subbu Nambi upgraded Grail to Buy from Neutral with a $100 price target.
Guggenheim
Subbu Nambi
Neutral -> Buy
upgrade
$100
2025-11-12
Reason
Guggenheim
Subbu Nambi
Price Target
$100
2025-11-12
upgrade
Neutral -> Buy
Reason
As previously reported, Guggenheim analyst Subbu Nambi upgraded Grail to Buy from Neutral with a $100 price target. While the firm acknowledges that Galleri is "not a perfect test" and "may not be the holy grail of cancer detection," the firm says it is still the leading commercially available MCED test and sees it having a significant prospective data moat compared to competitors. Though there are still meaningful unknowns around Medicare reimbursement for MCEDs and regulatory approvals, the firm says it "cannot ignore the opportunity" and Galleri's leading MCED market position.
Canaccord
Kyle Mikson
Buy
upgrade
$75 -> $85
2025-10-22
Reason
Canaccord
Kyle Mikson
Price Target
$75 -> $85
2025-10-22
upgrade
Buy
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Grail to $85 from $75 and keeps a Buy rating on the shares. The firm said they remain bullish following relatively positive study results and over $400 million (pending) added to the company's balance sheet, recognizing multiple questions remain regarding the perspective of regulators and clinicians. They also noted that after the market close on Friday, October 17, the company announced the performance and safety results from its registrational PATHFINDER 2 study and saidalthough the data improved from PATHFINDER 1, it is unclear if it will be adequate for FDA approval.
Morgan Stanley
Equal Weight
initiated
$20 -> $38
2025-06-26
Reason
Morgan Stanley
Price Target
$20 -> $38
2025-06-26
initiated
Equal Weight
Reason
Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $38, up from $20. While the firm sees significant long-term potential for Grail's Galleri MCED test, there are also inherent risks associated with novel technologies from a regulatory and reimbursement standpoint, the analyst tells investors. The firm is also updating estimates for Q1 results, noting that its Q2 and 2025 revenue estimates move to $36M and $151M, from prior forecasts of $37M and $149M, respectively.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Grail Inc (GRAL.O) is -8.67, compared to its 5-year average forward P/E of -2.17. For a more detailed relative valuation and DCF analysis to assess Grail Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.17
Current PE
-8.67
Overvalued PE
-0.01
Undervalued PE
-4.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.83
Undervalued EV/EBITDA
-4.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.90
Current PS
0.00
Overvalued PS
12.78
Undervalued PS
1.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 981.85% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 981.85% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GRAL News & Events

Events Timeline

(ET)
2025-12-01
16:30:00
Morgan Stanley Initiates Coverage on Grail with Equal Weight Rating and $110 Price Target
select
2025-11-18 (ET)
2025-11-18
10:01:37
Grail Experiences a 9.3% Decline
select
2025-11-18
09:07:46
Grail Executes 1 Million Share Block Trade at $80.65 Each
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-20WSJ
Abbott Set to Purchase Exact Sciences for $21 Billion

  • Acquisition Announcement: Abbott Laboratories has agreed to acquire Exact Sciences, a cancer diagnostics company, for approximately $21 billion.

  • Shareholder Benefits: Exact Sciences shareholders will receive $105 per share, leading to an 18% increase in the stock price during premarket trading.

[object Object]
Preview
1.0
11-19PRnewswire
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference

  • Company Presentation: GRAIL, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 3:00 p.m. ET, with live and replay webcasts available on their investor relations website.

  • Mission and Technology: GRAIL aims to detect cancer early when it is most treatable, utilizing next-generation sequencing, clinical studies, and advanced machine learning to identify multiple cancer types at earlier stages.

  • Comprehensive Cancer Care: The company's targeted methylation-based platform supports various aspects of cancer care, including early detection, risk stratification, and monitoring for treatment and recurrence.

  • Global Presence: GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom, emphasizing its commitment to alleviating the global burden of cancer.

[object Object]
Preview
2.0
11-18Benzinga
Major Stocks on the Rise Monday: Jazz Pharmaceuticals, Sigma Lithium, Zymeworks, and More

  • U.S. Stock Market Overview: U.S. stocks declined on Monday, with the Dow Jones index dropping over 100 points, while several individual stocks saw significant gains.

  • Jazz Pharmaceuticals Surge: Jazz Pharmaceuticals' shares rose 18% to $166.56 following positive results from a Phase 3 trial for its cancer treatment Ziihera.

  • Notable Stock Performances: PACS Group's shares jumped 49.5%, Sigma Lithium gained 30.5%, and Zymeworks rose 29.5%, among other notable stock increases.

  • Analyst Upgrades and Positive Data: Companies like Vita Coco and Alto Neuroscience received analyst upgrades, contributing to their stock price increases, while several firms reported strong clinical trial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Grail Inc (GRAL) stock price today?

The current price of GRAL is 104.705 USD — it has increased 3.47 % in the last trading day.

arrow icon

What is Grail Inc (GRAL)'s business?

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

arrow icon

What is the price predicton of GRAL Stock?

Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Grail Inc (GRAL)'s revenue for the last quarter?

Grail Inc revenue for the last quarter amounts to 36.19M USD, increased 26.32 % YoY.

arrow icon

What is Grail Inc (GRAL)'s earnings per share (EPS) for the last quarter?

Grail Inc. EPS for the last quarter amounts to -2.46 USD, decreased -37.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Grail Inc (GRAL)'s fundamentals?

The market is revising Upward the revenue expectations for GRAIL, Inc. (GRAL) for FY2025, with the revenue forecasts being adjusted by 1.59% over the past three months. During the same period, the stock price has changed by 183.68%.
arrow icon

How many employees does Grail Inc (GRAL). have?

Grail Inc (GRAL) has 1000 emplpoyees as of December 05 2025.

arrow icon

What is Grail Inc (GRAL) market cap?

Today GRAL has the market capitalization of 3.94B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free